Semaglutide indications: which conditions is it actually licensed for?

The biggest misconception: semaglutide is not one licence

Most people arrive at this question having read that semaglutide is a weight-loss medicine. That is partly true, but only for one brand, at one dose range, under one licence. Semaglutide is the active ingredient in three separate UK products. Ozempic (subcutaneous injection, up to 2mg weekly) and Rybelsus (oral tablets, 3mg to 14mg daily) are both licensed for type 2 diabetes management. Wegovy (subcutaneous injection, up to 2.4mg weekly, or 7.2mg with the higher-dose pen approved in April 2026) is licensed for chronic weight management. The NHS medicines information for semaglutide sets out these distinctions clearly.

A prescription for one brand cannot simply stand in for another. The doses differ, the titration schedules differ, and the clinical evidence underpinning each licence is distinct. If you are looking for treatment for weight management specifically, the relevant product is Wegovy, and even then, eligibility depends on your individual clinical picture, not the brand name alone. Our full semaglutide overview explains how the medicine works and why the brand distinction matters day to day.

Worth knowing: the oral formulation approved for weight loss is also semaglutide, but it is the Wegovy tablet (1.5mg to 25mg daily) rather than Rybelsus. They are not the same product, even though both are tablets and both contain semaglutide.

Semaglutide indications for weight management: the Wegovy licence in detail

The MHRA-approved indication for Wegovy covers adults with an initial BMI of 30 kg/m² or above, or adults with a BMI of 27 to 29.9 alongside at least one weight-related condition, such as high blood pressure, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease. Treatment is intended alongside a reduced-calorie diet and increased physical activity. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

NICE's appraisal of Wegovy (TA875) adds further conditions for NHS use: treatment should take place within a specialist weight management service with multidisciplinary support, and should not continue beyond two years. The NHS thresholds for specialist referral start at a BMI of 35 with at least one comorbidity, though lower for certain ethnic backgrounds. Private prescribing follows the licensed indication rather than the NICE commissioning criteria, which is why the private route and the NHS route have different eligibility conversations. You can find more on pricing and what private treatment involves on the Wegovy cost in the UK page.

NICE's recommendation is available in full at NICE TA875.

The newer indications: cardiovascular risk and liver disease

Semaglutide's approved indications have expanded beyond weight and blood sugar. Wegovy holds a UK authorisation for reducing the risk of major cardiovascular events in eligible adults with established cardiovascular disease and obesity. This was a significant development, because it moved semaglutide from a metabolic treatment to one with a primary cardiovascular endpoint, something the SELECT trial data supported.

Most recently, on 3 July 2026 the MHRA granted conditional approval for semaglutide (Wegovy) to treat MASH (metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease) in adults with moderate-to-advanced liver fibrosis. This is a distinct indication from weight management, even though weight reduction is part of the mechanism. Prescribers at specialist services manage these indications separately from routine weight-loss prescribing. If you are asking about semaglutide for a condition other than straightforward weight management, the right place to start is a conversation with your GP or specialist, not a private weight-loss clinic.

Certain health conditions also affect who can safely use semaglutide at all. There are contraindications and interactions that a prescriber reviews before any prescription, our page on Wegovy contraindications covers the main ones, and our clinical team's profile at our clinical team explains how prescribing decisions are made at nume.

How medications interact with semaglutide across its different indications

Because semaglutide slows gastric emptying, it can affect the absorption of other oral medicines, a consideration that applies across all its indications, whether someone is taking it for weight loss, blood glucose control, or cardiovascular risk reduction. Oral contraceptives are one specific example: for tirzepatide there is clear NHS guidance on adding a barrier method, but for semaglutide the evidence of reduced pill effectiveness is less established, and anyone with questions about specific medicines will find a detailed breakdown on our page covering whether semaglutide interacts with any medications.

Anyone taking insulin or sulphonylureas alongside semaglutide (usually in a diabetes context) needs monitoring for hypoglycaemia. More broadly, if you are already on regular medication for any of the conditions semaglutide is licensed to treat, your prescriber needs to see that list before starting or changing doses. A dedicated page on semaglutide with other medications goes through the main interactions, and there is further detail on what you cannot take alongside it. For anyone wanting the full picture of how semaglutide fits into the UK medicines landscape, the NHS semaglutide medicines page is a reliable starting point.

If you are considering Wegovy for weight management and want to know whether your current health profile and medication list fit the licensed indication, speaking to a prescriber is the clearest path. Speak to our prescribers through a free consultation and get a same-day clinical review of your individual situation.